Zihang Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zihang Xu has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Lin Su
Shanghai Key Laboratory of Health Identification and Assessment, School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
9 shared publications- Chunpu Zou
School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
6 shared publications Xiao Chen
Key Laboratory of Health Identification and Assessment, School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
6 shared publicationsYangzhuangzhuang Zhu
Shanghai Key Laboratory of Health Identification and Assessment, School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China
5 shared publicationsYifei Hou
School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
5 shared publicationsMingxi Liu
Shanghai Key Laboratory of Health Identification and Assessment, School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China
4 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (8) , 1-13
Osteoporosis in rheumatoid arthritis: a new perspective on risk factors and clinical prediction models
Osteoporosis (OP) is a prevalent and serious comorbidity in rheumatoid arthritis (RA), significantly increasing the fracture burden. Although early detection is crucial, OP screening in RA is often delayed, representing an unmet clinical need. Clinical prediction models (CPMs) offer a solution for early risk stratification, yet a synthesis that integrates RA-OP risk factors and evaluates existing CPMs is lacking. This review addresses this gap by delineating the multidimensional risk network for RA-OP and evaluating the development, performance, and applicability of current CPMs. We find that despite evolution from basic to sophisticated biomarker-integrated algorithms, most CPMs are constrained by modest sample sizes, insufficient external validation, and suboptimal clinical translatability. The current paradigm focuses predominantly on diagnosis rather than prognosis. To address these limitations, future research should aim to enhance the methodological rigor and generalizability of models, expand their predictive scope to encompass future risk of OP and fractures, and develop RA-specific fracture prediction tools that incorporate disease-specific pathophysiology, with performance rigorously benchmarked against established tools such as the fracture risk assessment tool (FRAX). Progress along these lines may help shift the management paradigm toward more proactive and personalized prevention, with the potential to improve long-term skeletal health outcomes in RA.
- 28 April 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (8) , 1-13
Open AccessOsteoporosis in rheumatoid arthritis: a new perspective on risk factors and clinical prediction models
Osteoporosis (OP) is a prevalent and serious comorbidity in rheumatoid arthritis (RA), significantly increasing the fracture burden. Although early detection is crucial, OP screening in RA is often delayed, representing an unmet clinical need. Clinical prediction models (CPMs) offer a solution for early risk stratification, yet a synthesis that integrates RA-OP risk factors and evaluates existing CPMs is lacking. This review addresses this gap by delineating the multidimensional risk network for RA-OP and evaluating the development, performance, and applicability of current CPMs. We find that despite evolution from basic to sophisticated biomarker-integrated algorithms, most CPMs are constrained by modest sample sizes, insufficient external validation, and suboptimal clinical translatability. The current paradigm focuses predominantly on diagnosis rather than prognosis. To address these limitations, future research should aim to enhance the methodological rigor and generalizability of models, expand their predictive scope to encompass future risk of OP and fractures, and develop RA-specific fracture prediction tools that incorporate disease-specific pathophysiology, with performance rigorously benchmarked against established tools such as the fracture risk assessment tool (FRAX). Progress along these lines may help shift the management paradigm toward more proactive and personalized prevention, with the potential to improve long-term skeletal health outcomes in RA.
- Open Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma
Portal vein tumor thrombus (PVTT) is among the most lethal complications of hepatocellular carcinoma (HCC), yet its molecular mechanisms and immune features remain poorly characterized. To address this gap, we performed a comprehensive multi-omics analysis of 99 specimens from 47 patients, integrating nCounter profiling, single-cell RNA sequencing, digital spatial profiling, and proteomics to construct the first spatial map of the PVTT microenvironment. These analyses revealed marked intratumoral heterogeneity and enrichment of myofibroblast-like cancer-associated fibroblasts (myCAFs) arising through a macrophage-to-myofibroblast transition. Nidogen-1 (NID1) was identified as a stromal driver of immune barriers, highly expressed in PVTT cores and associated with impaired antitumor immunity. Guided by these mechanistic insights, we repurposed acarbose, a Food and Drug Administration-approved drug, to inhibit the NID1 axis. Functional assays demonstrated that acarbose disrupted myCAF-mediated immune barriers, suppressed PVTT progression, and synergized with anti-programmed death-1 (anti-PD-1) therapy in preclinical models. Furthermore, analysis of an independent clinical cohort of 810 HCC patients revealed a substantially lower incidence of PVTT among those receiving acarbose, underscoring its translational potential. Collectively, these findings establish the immune–stromal landscape of PVTT, uncover NID1-driven stromal remodeling as a mechanism of immune evasion, and highlight drug repurposing as an immediately actionable strategy to improve outcomes in HCC with PVTT.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
Open AccessRepurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma
Portal vein tumor thrombus (PVTT) is among the most lethal complications of hepatocellular carcinoma (HCC), yet its molecular mechanisms and immune features remain poorly characterized. To address this gap, we performed a comprehensive multi-omics analysis of 99 specimens from 47 patients, integrating nCounter profiling, single-cell RNA sequencing, digital spatial profiling, and proteomics to construct the first spatial map of the PVTT microenvironment. These analyses revealed marked intratumoral heterogeneity and enrichment of myofibroblast-like cancer-associated fibroblasts (myCAFs) arising through a macrophage-to-myofibroblast transition. Nidogen-1 (NID1) was identified as a stromal driver of immune barriers, highly expressed in PVTT cores and associated with impaired antitumor immunity. Guided by these mechanistic insights, we repurposed acarbose, a Food and Drug Administration-approved drug, to inhibit the NID1 axis. Functional assays demonstrated that acarbose disrupted myCAF-mediated immune barriers, suppressed PVTT progression, and synergized with anti-programmed death-1 (anti-PD-1) therapy in preclinical models. Furthermore, analysis of an independent clinical cohort of 810 HCC patients revealed a substantially lower incidence of PVTT among those receiving acarbose, underscoring its translational potential. Collectively, these findings establish the immune–stromal landscape of PVTT, uncover NID1-driven stromal remodeling as a mechanism of immune evasion, and highlight drug repurposing as an immediately actionable strategy to improve outcomes in HCC with PVTT.
- 8 October 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 355 (Pt B) , 120727
Wu-wei-zi decoction reshapes the tumor immune microenvironment by targeting the IL-6/CD73 axis in myeloid-derived suppressor cells to inhibit non-small cell lung cancer
- 8 October 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 355 (Pt B) , 120727
Wu-wei-zi decoction reshapes the tumor immune microenvironment by targeting the IL-6/CD73 axis in myeloid-derived suppressor cells to inhibit non-small cell lung cancer
- Open Access
- 30 April 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-22
Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer
Background: Circulating tumor cells (CTCs) hold immense promise in guiding treatment strategies for advanced gastric cancer (GC). However, their clinical impact has been limited due to challenges in identifying epithelial-mesenchymal transition (EMT)-CTCs using conventional methods. Methods: To bridge this knowledge gap, we established a detection platform for CTCs based on the distinctive biomarker cell surface vimentin (CSV). A prospective study involving 127 GC patients was conducted, comparing CTCs enumeration using both EpCAM and CSV. This approach enabled the detection of both regular and EMT-CTCs, providing a comprehensive analysis. Spiking assays and WES were employed to verify the reliability of this marker and technique. To explore the potential inducer of CSV+CTCs formation, a combination of Tandem Mass Tag (TMT) quantitative proteomics, m6A RNA immunoprecipitation–qPCR (MeRIP–qPCR), single-base elongation- and ligation-based qPCR amplification method (SELECT) and RNA sequencing (RNA-seq) were utilized to screen and confirm the potential target gene. Both in vitro and in vivo experiments were performed to explore the molecular mechanism of CSV expression regulation and its role in GC metastasis. Results: Our findings revealed the potential of CSV in predicting therapeutic responses and long-term prognosis for advanced GC patients. Additionally, compared to the conventional EpCAM-based CTCs detection method, the CSV-specific positive selection CTCs assay was significantly better for evaluating the therapeutic response and prognosis in advanced GC patients and successfully predicted disease progression 14.25 months earlier than radiology evaluation. Apart from its excellent role as a detection marker, CSV emerges as a promising therapeutic target for attenuating GC metastasis. It was found that fat mass and obesity associated protein (FTO) could act as a potential catalyst for CSV+CTCs formation, and its impact on the insulin-like growth factor-I receptor (IGF-IR) mRNA decay through m6A modification. The activation of IGF-I/IGF-IR signaling enhanced the translocation of vimentin from the cytoplasm to the cell surface through phosphorylation of vimentin at serine 39 (S39). In a GC mouse model, the simultaneous inhibition of CSV and blockade of the IGF-IR pathway yielded promising outcomes. Conclusion: In summary, leveraging CSV as a universal CTCs marker represents a significant breakthrough in advancing personalized medicine for patients with advanced GC. This research not only paves the way for tailored therapeutic strategies but also underscores the pivotal role of CSV in enhancing GC management, opening new frontiers for precision medicine.
- 30 April 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-22
Open AccessExploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer
Background: Circulating tumor cells (CTCs) hold immense promise in guiding treatment strategies for advanced gastric cancer (GC). However, their clinical impact has been limited due to challenges in identifying epithelial-mesenchymal transition (EMT)-CTCs using conventional methods. Methods: To bridge this knowledge gap, we established a detection platform for CTCs based on the distinctive biomarker cell surface vimentin (CSV). A prospective study involving 127 GC patients was conducted, comparing CTCs enumeration using both EpCAM and CSV. This approach enabled the detection of both regular and EMT-CTCs, providing a comprehensive analysis. Spiking assays and WES were employed to verify the reliability of this marker and technique. To explore the potential inducer of CSV+CTCs formation, a combination of Tandem Mass Tag (TMT) quantitative proteomics, m6A RNA immunoprecipitation–qPCR (MeRIP–qPCR), single-base elongation- and ligation-based qPCR amplification method (SELECT) and RNA sequencing (RNA-seq) were utilized to screen and confirm the potential target gene. Both in vitro and in vivo experiments were performed to explore the molecular mechanism of CSV expression regulation and its role in GC metastasis. Results: Our findings revealed the potential of CSV in predicting therapeutic responses and long-term prognosis for advanced GC patients. Additionally, compared to the conventional EpCAM-based CTCs detection method, the CSV-specific positive selection CTCs assay was significantly better for evaluating the therapeutic response and prognosis in advanced GC patients and successfully predicted disease progression 14.25 months earlier than radiology evaluation. Apart from its excellent role as a detection marker, CSV emerges as a promising therapeutic target for attenuating GC metastasis. It was found that fat mass and obesity associated protein (FTO) could act as a potential catalyst for CSV+CTCs formation, and its impact on the insulin-like growth factor-I receptor (IGF-IR) mRNA decay through m6A modification. The activation of IGF-I/IGF-IR signaling enhanced the translocation of vimentin from the cytoplasm to the cell surface through phosphorylation of vimentin at serine 39 (S39). In a GC mouse model, the simultaneous inhibition of CSV and blockade of the IGF-IR pathway yielded promising outcomes. Conclusion: In summary, leveraging CSV as a universal CTCs marker represents a significant breakthrough in advancing personalized medicine for patients with advanced GC. This research not only paves the way for tailored therapeutic strategies but also underscores the pivotal role of CSV in enhancing GC management, opening new frontiers for precision medicine.
- 26 March 2024
- Published by Elsevier in Phytomedicine
- Vol. 130, 155544
Ze-Qi-Tang formula inhibits MDSCs glycolysis through the down-regulation of p21/Hif1α/Glut1 signal in psoriatic-like mice
- 26 March 2024
- Published by Elsevier in Phytomedicine
- Vol. 130, 155544
Ze-Qi-Tang formula inhibits MDSCs glycolysis through the down-regulation of p21/Hif1α/Glut1 signal in psoriatic-like mice
- 31 July 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 123, 110710
Targeting upregulation of the immunosuppressive activity of MDSCs with indirubin as a novel strategy to alleviate psoriasis
- 31 July 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 123, 110710
Targeting upregulation of the immunosuppressive activity of MDSCs with indirubin as a novel strategy to alleviate psoriasis
- 16 April 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 313, 116491
The Tian-Men-Dong decoction suppresses the tumour-infiltrating G-MDSCs via IL-1β-mediated signalling in lung cancer
- 16 April 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 313, 116491
The Tian-Men-Dong decoction suppresses the tumour-infiltrating G-MDSCs via IL-1β-mediated signalling in lung cancer
- 1 November 2020
- Published by Elsevier in Cancer Letters
- Vol. 493, 167-177
Thevebioside, the active ingredient of traditional Chinese medicine, promotes ubiquitin-mediated SRC-3 degradation to induce NSCLC cells apoptosis
- 1 November 2020
- Published by Elsevier in Cancer Letters
- Vol. 493, 167-177
Thevebioside, the active ingredient of traditional Chinese medicine, promotes ubiquitin-mediated SRC-3 degradation to induce NSCLC cells apoptosis